Mitsu Chem Plast Q1 FY27 Earnings Call — Analysis (BSE: 540078)
Mitsu Chem Plast reported strong Q1FY27 profitability with EBITDA rising 209.5% YoY to ₹15.49 Cr (16.29% margin) driven by product-mix rationalisation and operational efficiencies, while reiterating its ₹1,000 Cr revenue target by FY28.
Result quality: stable — Results context unavailable. Management sentiment: optimistic.
The take
Q1FY27 Total Income ₹95.33 Cr ( +11.62% YoY ) . New guidance — FY28 annual revenue target ₹1,000 Cr . New story: Value-added mix and SKU rationalisation .
Results
Total income grew 11.62% YoY to ₹95.33 Cr, while EBITDA surged 209.5% to ₹15.49 Cr (margin expanded 1,041 bps YoY to 16.29%) and PAT surged 566.2% to ₹8.74 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total Income | ₹95.33 Cr | +11.62% | yoy · Q1FY27 · vs ₹85.40 Cr in Q1FY26 |
| EBITDA | ₹15.49 Cr | +209.50% | yoy · Q1FY27 · vs ₹5.01 Cr in Q1FY26 |
| EBITDA | ₹15.49 Cr | +8.91% | sequential · Q1FY27 · vs ₹14.23 Cr in Q4FY26 |
| EBITDA Margin | 16.29% | +1041bps | yoy · Q1FY27 · vs 5.87% in Q1FY26 |
| Net Profit | ₹8.74 Cr | +566.23% | yoy · Q1FY27 · vs ₹1.31 Cr in Q1FY26 |
| Net Profit | ₹8.74 Cr | +13.23% | sequential · Q1FY27 · vs ₹7.72 Cr in Q4FY26 |
| Net Profit Margin | 9.18% | +764bps | yoy · Q1FY27 · vs 1.54% in Q1FY26 |
| Diluted EPS | ₹6.44 | +563.92% | yoy · Q1FY27 · vs ₹0.97 in Q1FY26 |
Guidance
Management reaffirmed its long-term target to achieve ₹1,000 Cr in annual revenue by FY28 and expects commercial production for the IBC project to commence in Q3FY27.
What management committed to
- The company continues to work towards its long-term objective of achieving INR 1,000 crores in annual revenue by FY28. — INR 1,000 crores, FY28
- [Mitsu Chem Plast] will start commercial production for the IBC project most probably in Q3 [FY27]. — Q3FY27
- Double-digit EBITDA margin will remain the same for sure, with sustainable margins around 10% to 12% or 10% to 13%. — 10% to 12%, FY27
- Across the expanded capacity of ~36,000 MTPA, capacity utilisation will approximately remain in the 64%, 65% or 70% range in FY27. — 64%, 65% or 70%, FY27
Key themes
Margin expansion through mix rationalisation
How the narrative shifted
- Value-added mix and SKU rationalisation: Management is actively weeding out low-margin/profit-draining SKUs while expanding proprietary and value-added healthcare furniture (Furnastra) and custom moulding lines.
- Raw material pass-through mechanism: Company procures 100% domestic raw material and passes cost movements to customers with a one-month lag on a cost-plus formula.
- Scale expansion toward FY28 milestone: Capacity addition of 3,550 MTPA and the upcoming Q3FY27 IBC commercialisation are positioned as critical stepping stones toward the ₹1,000 Cr revenue target.
Operational commentary
- Added 3,550 MTPA manufacturing capacity to existing base of 32,450 MTPA (total capacity now exceeds 36,000 MTPA across 4 plants with 53 blow moulding and 22 injection moulding machines); facility is already operational.
- Executing SKU rationalisation by weeding out low-margin/profit-draining products while prioritising higher-value custom mouldings, hospital furniture (Furnastra), and specialised packaging.
- Packaging business constitutes ~80% of revenue, while healthcare/hospital furniture components contribute ~19.80%.
- Export footprint spans 17 countries, currently representing ~2% of total sales with long-term international expansion ongoing.
- Customer additions remained strong with 30+ clients added in Q1FY27, following 150+ customer additions in FY26.
- Commercial production for the Intermediate Bulk Container (IBC) project is slated to commence in Q3FY27 using dedicated machinery.
Analyst Q&A
Q. What led to the sharp margin expansion to ~16% and is this level sustainable given input cost volatility?
Attributed expansion to SKU rationalisation, operational efficiencies, and higher value-added product mix. Noted raw material costs are passed through to customers on a 1-month lag, and guided that 10-12% (or 10-13%) represents normalised sustainable EBITDA margin with double-digit margins assured.
Q. What is the capex and operational timeline for the proposed 3,550 MTPA capacity addition?
Incurred approximately ₹2 Cr capex funded via a mix of internal accruals and debt; the capacity is already fully installed and online.
Q. What is the status, capital outlay, and revenue potential for the upcoming IBC project?
Confirmed commercial operations are expected in Q3FY27 with separate dedicated machinery, but declined to disclose specific investment outlay or revenue numbers, stating details will be announced later.
Q. What are the planned revenue mix and trajectory required to reach the ₹1,000 Cr revenue target by FY28 from the current quarterly run rate of ~₹95 Cr?
Acknowledged the required growth step-up, citing that new capacity additions and the IBC project commencing Q3FY27 will drive volumes, while maintaining the packaging vs healthcare furniture ratio around 80:20.
Research and educational content only. Not investment advice.